TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02374567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biperiden

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomepromazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluphenazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perphenazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioridazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melperone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pipamperone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromperidol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benperidol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flupentixol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorprothixene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluspirilene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimozide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulpiride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiapride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothipendyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Study: NCT01434732

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Cord Clamping
Description: The umbilical cord will be clamped soon after birth without any milking of the umbilical cord.
Study: NCT02358304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nasal spray calcitonin
Description: recurrence rate of aggressive CGCG will be recorded after the use of nasal spray calcitonin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01269307

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1:1 ketamine-propofol mixture sedation
Description: Prepare Ketamine and Propofol 10mg/cc of ketamine 10mg/cc of propofol mix 1:1 in 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus. Repeat dose 0.025 - 0.05 every 60-90 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5-1 cc. Note - 1 cc = 5mg of propofol and 5mg of ketamine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Sedation
Description: Prepare Propofol 10mg/cc of propofol 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus over 30 seconds. Repeat dose 0.025 - 0.05 cc/kg every 30-60 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5 cc Note - 1 cc = 10 mg of propofol
Study: NCT02314832

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block
Description: ultrasound guided saphenous nerve block in the adductor canal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral nerve block
Description: ultrasound guided femoral nerve block
Study: NCT04300036

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: longan syrup
Description: Subjects will take 15 ml of longan syrup once a day for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo syrup
Description: Subjects will take 15 ml of placebo syrup once a day for 3 months
Study: NCT01078649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1143 (AT-406)
Description: Oral Debio 1143 (AT-406) will be administered in a dose escalation study to determine the maximally tolerated dose in humans. Patients will receive Debio 1143 (AT-406) on days 1-5, and 15-19 of a 28 day cycle, or days 1-5 of a 21 day cycle, repeated until progression or unacceptable toxicity occurs.
Study: NCT02808910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudged to eat less added salt and more other seasonings

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudged to eat less added salt and more other seasonings

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudged to avoid foods high in salt content, and to choose foods low in salt content

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudged to avoid foods high in salt content, and to choose foods low in salt content
Study: NCT01940809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02808910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudged to eat more vegetables

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudged to eat more vegetables

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudged to eat smaller portions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudged to eat smaller portions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudged to eat less calorie-dense food

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudged to eat less calorie-dense food
Study: NCT02220426

Intervention type: DRUG
Group type: OTHER
Intervention: Xenon
Description: Inhalation of hyperpolarized xenon gas
Study: NCT02448589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-119
Study: NCT01940809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT00192504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab
Description: Single dose of Motavizumab at a dose of 3 mg/kg administered intravenously (in the vein) on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab
Description: Single dose of Motavizumab at a dose of 15 mg/kg administered intravenously (in the vein) on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab
Description: Single dose of Motavizumab at a dose of 30 mg/kg administered intravenously (in the vein) on Day 0

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo administered intravenously (in the vein) on Day 0
Study: NCT01593800

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bio-25
Description: Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
Study: NCT01068015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: behavior intervention and male circumcision
Description: MSM in intervention arm can receive circumcision service for free, POL intervention, intensive HIV counseling and intensive condom promotion.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: behavior intervention and male circumcision
Description: MSM in intervention arm can receive circumcision service for free, POL intervention, intensive HIV counseling and intensive condom promotion.
Study: NCT04139967

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiation therapy
Description: 25 Gray in 5 fractions over 5-7 days
Study: NCT04789018

Intervention type: OTHER
Intervention: Educational Intervention
Description: Attend virtual genetics board

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT03693079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wet cupping therapy
Description: CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46). The cupping technique procedure was conducted in five phases:~1. Primary suction; cups are left attached to the skin for 5 minutes.~2. Area disinfection; areas are wiped with sterile gauze after disinfection with povidone iodine.~3. Scarification; Superficial incisions (20-30 gauge), 5 mm length and 1-2 mm depth, are made on the skin with a sterile, number 11 surgical blade.~4. Bloodletting and secondary suction; the cups which had been previously removed are placed again on the scarified areas Blood leaks from the capillary vessels of the skin and subcutaneous tissue and fills the cups, which are left in place for 15 minutes.~5. Removing and dressing; the cups full of blood are removed. The areas of application are wiped with sterile gauze and then a dressing is applied
Study: NCT02297828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boussignac CPAP
Description: Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi face mask
Description: Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).
Study: NCT02157142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HLT Transcatheter Aortic Valve System
Description: Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
Study: NCT02417012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: U-TURN
Description: Participants in this group will receive individual and group based interventions on obtaining and maintaining a healthy lifestyle, while having the pharmacological treatment regulated

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard individual diabetes support
Study: NCT02890979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swallowable Sponge Cell Sampling Device
Description: Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
Study: NCT00265343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: 5-10 mg sublingually twice daily for 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 5-20 mg by mouth once daily for 26 weeks
Study: NCT00573755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: given orally
Study: NCT04789018

Intervention type: OTHER
Intervention: Interview
Description: Complete interview
Study: NCT02020811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentinel
Study: NCT04382066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin 1.5 mg/day
Description: Plitidepsin 1.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin 2.0 mg/day
Description: Plitidepsin 2.0 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin 2.5 mg/day
Description: Plitidepsin 2.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin.
Study: NCT01979692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: confocal laser microscopy CLM at trans thoracic needle biopsy TTNB

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT guided trans thoracic needle biopsy
Study: NCT01625364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHARP program
Description: Staying Healthy-Asthma Responsible and Prepared is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregivers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open Airways for Schools
Description: OAS is a non-academic asthma health education program for elementary students with asthma and their parents.
Study: NCT00573755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: given orally
Study: NCT03908918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness app
Description: Mobile app-delivered mindfulness intervention delivered over 4 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Mindfulness app
Description: Mobile app-delivered mindfulness intervention delivered over 4 weeks.
Study: NCT01996956

Intervention type: OTHER
Group type: OTHER
Intervention: volume expansion
Description: fluid loading of 10 ml/kg colloid or blood product
Study: NCT01657734

Intervention type: OTHER
Intervention: MR imaging
Description: MR imaging

Intervention type: OTHER
Intervention: MR imaging
Description: MR imaging
Study: NCT00020878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Dosing will occur for a total of 6 months. 400 mg by mouth twice daily.
Study: NCT00387725

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rLP2086
Description: Vaccine administered at 0, 1, and 6 months
Study: NCT04279509

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Core Biopsy
Description: Performed up to a maximum of 3 time points - baseline upon study enrolment, at the completion of treatment, and upon disease progression.~Four to six tumour core samples will be obtained at each time point. At least two tumour cores will be sent fresh to Invitrocue Pte Ltd for generation of patient-derived organoids for drug-panel screening, at least 1-2 tumour cores at each time point will be stored in formalin and paraffin-embedded for immunohistochemistry analysis of biomarkers, while the remaining 1-2 tumour cores will be stored in liquid nitrogen for subsequent DNA, RNA and protein extraction for biomarker studies including gene expression and proteomics analyses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Germline DNA at baseline for pharmacogenetics analysis. Serial plasma samples for circulating tumour cells and biomarkers, at baseline, prior to day 1 of each cycle while on treatment, at the end of treatment (either upon disease progression or upon completion of predetermined cycles of chemotherapy).
Study: NCT02372539

Intervention type: OTHER
Intervention: Diabetes
Description: All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators

Intervention type: OTHER
Intervention: Control Group
Description: All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
Study: NCT01226134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itopride,
Description: Itopride,50 mg capsules,thrice a day,for Four weeks
Study: NCT00387725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: Vaccine administered at 0, 1, and 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: Vaccine administered at 0, 1, and 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: Vaccine administered at 0, 1, and 6 months
Study: NCT03873935

Intervention type: OTHER
Intervention: Evaluation of periodontal status
Description: Clinical examination

Intervention type: OTHER
Intervention: Evaluation of periodontal status
Description: Clinical examination
Study: NCT01226134

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules,thrice a day for four weeks
Study: NCT00411229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1,000 mg/m² twice daily. Film coated tablets of 500 mg, 150mg.
Study: NCT03873935

Intervention type: OTHER
Intervention: Evaluation of periodontal status
Description: Clinical examination
Study: NCT00573755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: given orally
Study: NCT00411229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: IV infusion, 130mg/m²
Study: NCT00573755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: given orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: given orally
Study: NCT02271295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparine
Description: Enoxaparine 4000UI/day during 24 months
Study: NCT00743418

Intervention type: DEVICE
Group type: OTHER
Intervention: GPS modem and RFID
Description: The participant will take the GPS kit with him/her everywhere during the whole day for a period of 4 weeks. The GPS tracking kit consists of a GPS receiver with a GSM modem, an RF transmitter contained in a wrist-watch and a monitoring unit located in the home that enables researchers to know whenever the tracked person leaves home. The waterproof RF transmitter will allow researchers to know whether or not research subjects leave home with the GPS device and if they are carrying the device or not at a given moment.

Intervention type: DEVICE
Group type: OTHER
Intervention: GPS modem and RFID
Description: The participant will take the GPS kit with him/her everywhere during the whole day for a period of 4 weeks. The GPS tracking kit consists of a GPS receiver with a GSM modem, an RF transmitter contained in a wrist-watch and a monitoring unit located in the home that enables researchers to know whenever the tracked person leaves home. The waterproof RF transmitter will allow researchers to know whether or not research subjects leave home with the GPS device and if they are carrying the device or not at a given moment.

Intervention type: DEVICE
Group type: OTHER
Intervention: GPS modem and RFID
Description: The participant will take the GPS kit with him/her everywhere during the whole day for a period of 4 weeks. The GPS tracking kit consists of a GPS receiver with a GSM modem, an RF transmitter contained in a wrist-watch and a monitoring unit located in the home that enables researchers to know whenever the tracked person leaves home. The waterproof RF transmitter will allow researchers to know whether or not research subjects leave home with the GPS device and if they are carrying the device or not at a given moment.
Study: NCT03899909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3121 SAD
Description: GLPG3121 oral suspension, single ascending doses
Study: NCT01442415

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle modification
Description: Weekly lifestyle modification sessions including dietary counseling and physical activity
Study: NCT00405756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide: Double-blind Induction
Description: Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
Study: NCT03573986

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [18F]fluoromisonidazole
Description: positron emitting radiopharmaceutical that has been studied in vivo in humans for measurement of regional hypoxia in a number of tumor types with positron emission tomography (PET/CT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (Avastin, Genentech/Roche) is a humanized monoclonal antibody that binds to VEGF preventing its interaction with VEGFRs resulting in suppression of VEGF signaling.